Theodora Ntetsika

Theodora Ntetsika

Auto-generated profile, based on publicly available information

Theodora Ntetsika

Department of Clinical Neuroscience Karolinska Institutet Stockholm Sweden

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2021 in Movement Disorders
Verified
Journal Article
Open access
PDF file
IMIoanna Markaki
Ioanna Markaki
TNTheodora Ntetsika
Theodora Ntetsika
KSKimmo Sorjonen
Kimmo Sorjonen
Per SvenningssonPer Svenningsson
Per Svenningsson
FGfor the BioPark Study Group
for the BioPark Study Group
Background: The interplay between glycemic control and Parkinson's disease (PD) has long been recognized but not fully understood.Objectives: To investigate the association of glycated hemoglobin (HbA1c) levels with motor and cognitive symptom progression in a prospective PD cohort.Methods: Of 244 PD patients, 17 had low HbA1c (≤30 mmol/mol), 184 were euglycemic (HbA1c 31–41 mmol/mol), 18 had high HbA1c (HbA1 ≥42 mmol/mol), and 25 had diabetes mellitus (DM). Survival analysis was applied on time until Hoehn and Yahr stage ≥3 (motor outcome) and until mild cognitive impairment.Results: Low HbA1c (HR 2.7; 95% CI 1.3–6; P = 0.01) as well as high HbA1c (HR 3.6; 95% CI 1.5–8.9; P = 0.005) but not DM were independent predictors of unfavorable motor outcome.Conclusions: Both high and low HbA1c levels may be associated with motor symptom progression in PD; however, further studies are needed to confirm these findings and increase understanding regarding causality. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society

3 April 2024 in Neural Regeneration Research
Verified
Journal Article
Open access
TNTheodora Ntetsika
Theodora Ntetsika
SCSergiu-Bogdan Catrina
Sergiu-Bogdan Catrina
IMIoanna Markaki
Ioanna Markaki
Type 2 diabetes mellitus and Parkinson’s disease are chronic diseases linked to a growing pandemic that affects older adults and causes significant socio-economic burden. Epidemiological data supporting a close relationship between these two aging-related diseases have resulted in the investigation of shared pathophysiological molecular mechanisms. Impaired insulin signaling in the brain has gained increasing attention during the last decade and has been suggested to contribute to the development of Parkinson’s disease through the dysregulation of several pathological processes. The contribution of type 2 diabetes mellitus and insulin resistance in neurodegeneration in Parkinson’s disease, with emphasis on brain insulin resistance, is extensively discussed in this article and new therapeutic strategies targeting this pathological link are presented and reviewed.

5 September 2023 in Movement Disorders
Verified
Journal Article
Open access
IMIoanna Markaki
Ioanna Markaki
WPWojciech Paslawski
Wojciech Paslawski
TNTheodora Ntetsika
Theodora Ntetsika
LELisa Engesvik
Lisa Engesvik
SCSergiu‐Bogdan Catrina
Sergiu‐Bogdan Catrina
Per SvenningssonPer Svenningsson
Per Svenningsson

19 August 2021 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
IMIoanna Markaki
Ioanna Markaki
TNTheodora Ntetsika
Theodora Ntetsika
Per SvenningssonPer Svenningsson
Per Svenningsson